Literature DB >> 16850370

MELD-based liver allocation: who is underserved?

Scott W Biggins1, Kiran Bambha.   

Abstract

Deceased-donor livers are a scarce, lifesaving resource. For patients whose lives depend upon liver transplantation, policies for prioritizing allograft allocation are of ultimate importance. In the current paradigm, donor livers are allocated on the basis of medical urgency. Thus, the onus is on the transplant community to refine the allocation system continuously so that livers are targeted to patients who need them most. The current model for end-stage liver disease (MELD)-based allocation system works well, accurately predicting short-term mortality for the majority (83 to 87%) of waitlisted candidates. However, there are patients with liver diseases whose survival is dependent upon factors other than the severity of the liver disease and who may not manifest derangements in their MELD parameters. Such patients may be underserved by current MELD policies. This article reviews the development of MELD and the MELD-based liver allocation system and addresses issues relevant to whether this system may be improved.

Entities:  

Mesh:

Year:  2006        PMID: 16850370     DOI: 10.1055/s-2006-947291

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  17 in total

Review 1.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  Patient, center and geographic characteristics of nationally placed livers.

Authors:  J C Lai; J P Roberts; E Vittinghoff; N A Terrault; S Feng
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

3.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

4.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

5.  Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Authors:  Nadim Mahmud; Maarouf A Hoteit; David S Goldberg
Journal:  Liver Transpl       Date:  2020-08       Impact factor: 5.799

Review 6.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  Liver transplantation for malignancies.

Authors:  Bijan Eghtesad; Federico Aucejo
Journal:  J Gastrointest Cancer       Date:  2014-09

8.  Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis.

Authors:  Avash Kalra; Joel P Wedd; Kiran M Bambha; Jane Gralla; Lucy Golden-Mason; Christine Collins; Hugo R Rosen; Scott W Biggins
Journal:  Liver Transpl       Date:  2017-02       Impact factor: 5.799

Review 9.  Model for end-stage liver disease: end of the first decade.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Clin Liver Dis       Date:  2011-10-01       Impact factor: 6.126

10.  Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.

Authors:  Allison J Kwong; Jennifer C Lai; Jennifer L Dodge; John P Roberts
Journal:  Liver Transpl       Date:  2015-11       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.